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Psychopathology is a risk factor for accelerated biological aging and early mortality. We examined associations between broad
underlying dimensions of psychopathology (reﬂecting internalizing and externalizing psychiatric symptoms), PTSD, and ageadjusted GrimAge (“GrimAge residuals”), a DNA methylation biomarker of mortality risk relative to age. We also examined
neurobiological correlates of GrimAge residuals, including neurocognitive functioning, blood-based biomarkers (of inﬂammation,
neuropathology, metabolic disease), and cortical thickness. Data from two independent trauma-exposed military cohorts (n = 647
[62.9% male, Mage = 52], n = 434 [90% male, Mage = 32]) were evaluated using linear regression models to test associations
between GrimAge residuals, psychopathology, and health correlates. Externalizing psychopathology signiﬁcantly predicted
GrimAge residuals in both cohorts (ps < 0.028). PTSD predicted GrimAge residuals in the younger (p = 0.001) but not the older
cohort. GrimAge residuals were associated with several neurobiological variables available in the younger cohort, including
cognitive disinhibition (padj = 0.021), poorer memory recall (padj = 0.023), cardiometabolic pathology (padj < 0.001), oxidative stress
(padj = 0.003), astrocyte damage (padj = 0.021), inﬂammation (C-reactive protein: padj < 0.001; IL-6: padj < 0.001), and immune
functioning (padj < 0.001). A subset of inﬂammatory and neuropathology analytes were available in the older cohort and showed
associations with GrimAge residuals (IL-6: padj < 0.001; TNF-α: padj < 0.001). GrimAge residuals were also associated with reduced
cortical thickness in right lateral orbitofrontal cortex (padj = 0.018) and left fusiform gyrus (padj = 0.030), which are related to
emotion regulation and facial recognition, respectively. Psychopathology may be a common risk factor for elevated mortality risk.
GrimAge could help identify those at risk for adverse health outcomes and allow for early disease identiﬁcation and treatment.
Translational Psychiatry (2022)12:406 ; https://doi.org/10.1038/s41398-022-02164-w

INTRODUCTION
Psychopathology is a risk factor for premature morbidity and
mortality [1]. This association has been reported for numerous
psychiatric diagnoses, including posttraumatic stress disorder
(PTSD) [2], major depressive disorder (MDD) [3], anxiety [4],
antisocial personality disorder [5], substance use disorders [6], and
alcohol and nicotine dependence [7]. Psychopathology may be a
shared risk factor for premature morbidity and mortality,
suggesting the potential for common biological pathways linking
psychiatric stress to adverse health outcomes.
Shared variance across common psychiatric disorders is reﬂected
in broad, underlying dimensions capturing internalizing and
externalizing psychopathology. These underlying spectra of psychopathology offer a useful framework for evaluating shared health
burden across individual psychiatric disorders as they may have
greater biological relevance than individually deﬁned disorders [8].
Consistent with this, there is evidence that the internalizing

dimension, which underlies individual mood and anxiety disorders,
is associated with a greater ability to predict mortality risk over a
20-year period relative to individual disorders alone [9]. This suggests
that psychiatric distress shared across internalizing disorders is a
common factor that increases the risk for premature morbidity and
mortality. However, no study has examined if the risk is equivalent for
primarily distress-based disorders (e.g., major depression, dysthymia,
and generalized anxiety disorder) as compared to fear-based
disorders (e.g., panic and phobic disorders), which are the two
lower-order factors of the higher-order internalizing dimension.
Additionally, although individual externalizing disorders have been
shown to predict early death [5], the relative associations between
higher-order dimensions of externalizing (e.g., characterized by
impulsivity, substance use, and antisociality) in comparison to
internalizing have yet to be examined. PTSD shows genotypic [10]
and phenotypic [11] associations with both internalizing and
externalizing dimensions of psychopathology, highlighting the need
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to investigate its inﬂuence on premature mortality in conjunction
with both of these broad dimensions of psychopathology. A better
understanding of associations between psychopathology and risk for
early death would improve targeted interventions for those at
greatest risk. Biomarkers of disease and death are critical tools for
assessing risk, tracking change over time, and informing the
biological mechanisms that link psychiatric stress to adverse health
outcomes. A recently developed blood-based DNA methylation
(DNAm) biomarker of mortality risk referred to as “GrimAge” [12] may
prove useful for these purposes. GrimAge was developed by ﬁrst
identifying blood-based molecules previously associated with
mortality and morbidity, which were (in addition to self-reported
smoking pack-years) then regressed on thousands of DNAm loci to
generate DNAm-based surrogate biomarkers of these molecules and
behaviors. Next, time-to-death due to all-cause mortality was
regressed on these surrogate variables, creating a weighted
composite score, which was then linearly transformed to be in the
unit of years. Regressing the composite DNAm GrimAge score on
chronological age yields a residual variable that indexes mortality risk
relative to that expected based on age (“GrimAge residuals”). After
adjusting for mortality risk factors, GrimAge residuals strongly
predicted (p = 5.7E-29) lifespan and time to age-related diseases
(e.g., heart disease) in initial validation studies in several large,
longitudinal epidemiological cohorts (n = 6,935) comprising men
and women varying of mean age from 56.2 to 67 years [12].
GrimAge differs from prior DNAm-based indicators of biological
aging, such as the Horvath [13] and Hannum et al. [14] algorithms, as
it was not trained on chronological age, but rather time-to-death.
This is important because the DNAm age calculators are so accurate
in predicting chronological age (rs ~0.90; Wolf et al., 2018) that there
is little residual variance left to index accelerated (or decelerated)
aging and thus effect sizes for associations between environmental
variables and accelerated aging in DNAm tend to be quite small [15].
Though GrimAge and other DNAm age estimates are strongly
inﬂuenced by chronological age, after partialling out this effect,
GrimAge residuals were found to be only weakly correlated
(rs = 0.00 – −0.02) with Horvath and Hannum residual estimates
[16]. An exception to this is PhenoAge [17], another DNAm-based
predictor of lifespan, which, when adjusted for chronological age, has
been shown to be moderately correlated with age-adjusted GrimAge
(r = 0.40) [16]. Still, GrimAge outperforms each of these other DNAmbased biomarkers in its prediction of time-to-death and other healthrelated metrics [12, 16].
In addition to its ability to predict lifespan and healthspan, ageadjusted GrimAge has been associated with neurodegeneration and
other age-related changes in brain health. In a recent study of 709
elderly Scottish individuals [18], higher GrimAge residuals (indexing
greater risk of death than would be expected based on age) were
associated with poorer neurocognitive functioning and decreased
neural integrity, including decreased brain volume and increased
volume of vascular brain lesions. Further, a recent study of traumaexposed individuals reported that higher GrimAge residuals were
associated with reduced cortical thickness in the right lateral
orbitofrontal cortex and the right posterior cingulate cortex [19].
Follow-up analyses indicated the right lateral orbitofrontal cortex
effect was evident among individuals with PTSD, but not controls.
Thus, trauma exposure and psychopathology may increase the risk
for epigenetic aging and associated neuropathology.
Consistent with this, higher GrimAge residuals have been
reported among PTSD [19, 20] and MDD [21] cases compared to
controls. PTSD symptom course has also been associated with
changes in GrimAge residuals over time [20]. Effect sizes for
psychiatric cases vs. controls have been markedly greater in
studies examining GrimAge residuals (e.g., Cohen’s ds = 0.54–0.64)
[20, 21] compared to studies focused on other DNAm age
residuals (e.g., Cohen’s ds = 0.18–0.42) [22, 23].
It is important to comprehensively examine the clinical utility of
GrimAge by evaluating its associations with a range of age-related

neurobiological factors, such as neural integrity, cognitive functioning
(e.g., inhibitory control, verbal memory recall), and biomarkers of
neuropathology, inﬂammation, oxidative stress, immune, and metabolic functioning, all of which are associated with aging and mortality
[15, 24–26]. Recent advancements in Single Molecule Array (Simoa®)
technology have resulted in the ability to digitally measure analytes at
very low concentrations (e.g., sub-picomolar lower limits of detection)
with a high degree of precision, maximizing early detection of
biomarkers associated with health outcomes that occur many years
later. For example, several Simoa® neuropathology biomarkers (tau,
neuroﬁlament light chain, amyloid-ß species) have demonstrated the
ability to predict later conversion to Alzheimer’s disease among
individuals without current symptoms [27]. GrimAge has yet to be
examined in association with these high sensitivity early markers of
inﬂammation and neuropathology. Testing these associations is
essential for risk prediction and reduction, particularly among young
individuals for whom the capacity to alter disease course via
prevention and intervention efforts may be most successful.
The primary aim of this study was to examine associations
between internalizing and externalizing psychopathology dimensions and PTSD with GrimAge residuals in two independent cohorts.
We hypothesized that GrimAge residuals would evidence positive
associations with PTSD and the internalizing and externalizing
psychopathology dimensions. The second aim was to examine the
neurobiological correlates of shortened time-to-death, as indexed by
GrimAge residuals. We expected GrimAge residuals to be associated
with: (a) greater pathology in neurologic (neuroﬁlament light, glial
ﬁbrillary acidic protein [GFAP], tau, brain-derived neurotrophic factor
[BDNF], amyloid ß 40 and 42, phosphorylated neuroﬁlament heavy
chain, neuron-speciﬁc enolase [NSE]), inﬂammatory (C-reactive
protein [CRP], interleukin 6 and 10 [IL-6, IL10], eotaxin, tumor
necrosis factor [TNF-α]), immune (white blood cells), metabolic (e.g.,
blood pressure, triglycerides, insulin), and oxidative stress (gammaglutamyl transferase [GGT]) markers; (b) neurocognitive deﬁcits; and
(c) reduced cortical thickness in frontal regions.

MATERIALS AND METHODS
Participants

National Center for PTSD (NCPTSD) cohort. The ﬁrst cohort was comprised
of 647 participants with DNAm data enrolled in one of two VA NCPTSD
studies with identical comprehensive psychiatric diagnostic assessments,
allowing the data to be combined. The NCPTSD cohort was comprised of
trauma-exposed veterans and a subset of their spouses; the cohort was
majority male (62.9%) with a mean age of 52 years (SD = 10.6). A detailed
description of these protocols is provided in Logue et al. [28].

Translational Research Center for TBI and stress disorders (TRACTS) cohort.
The second cohort (n = 434) consisted of young (Mage = 32.4, SD = 8.6)
primarily male (90%) US veterans enrolled in a large, ongoing prospective
study of psychological and brain trauma associated with the post-9/11
conﬂicts (The Translational Research Center for TBI and Stress Disorders/
TRACTS) [29]. Participants completed a comprehensive psychiatric evaluation,
including neurocognitive and psychological assessments. Participants also
provided blood samples for genetic and metabolic testing and underwent
magnetic resonance imaging (MRI) of the brain. Individuals with moderate-tosevere traumatic brain injury (TBI; n = 15) were excluded from analyses
investigating neurobiological correlates of GrimAge. The VA Boston Institutional Review Board approved all study procedures in both cohorts.

Measures
Psychiatric measures (Both cohorts). In both cohorts, PTSD was assessed
with the Clinician-Administered PTSD Scale (CAPS) [30], a structured
diagnostic interview assessing the frequency and intensity of DSM-IV PTSD
symptom criteria. Frequency and intensity ratings were summed to create
a dimensional score of lifetime PTSD severity. In both cohorts, lifetime Axis
I disorders were assessed using the Structured Clinical Interview for DSM-IV
(SCID-IV) [31]. In the NCPTSD cohort, all items were administered without
applying standard “skip-out” rules, permitting both symptom count scores
and diagnostic determinations. In the TRACTS cohort, only diagnostic
Translational Psychiatry (2022)12:406
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determinations were available for analysis as administration of the SCID
followed the standard skip-out procedures. Antisocial personality disorder
(ASPD) was assessed in the NCPTSD cohort only using the SCID for
Personality Disorders [32] and the International Personality Disorders Exam
[33], which were harmonized following the procedure detailed in Miller
et al. [34] (see also Supplementary Materials).
GrimAge (Both cohorts). DNA was isolated from peripheral blood samples.
In both cohorts, genotypes were assayed on the Illumina
HumanOmni2.5–8 array and DNAm on the Illumina Inﬁnium MethylationEPIC array. Genotyping and DNAm quality control methods are described
in the Supplementary Materials, as are the calculation procedures for
GrimAge, other DNAm age estimates, and ancestry principal components
(PCs). An index of age-adjusted GrimAge was created by regressing
GrimAge on chronological age and saving the residuals (“GrimAge
residuals”). Conceptually, positive residual values index mortality risk that
is elevated compared to chronological age, while negative residual values
suggest reduced mortality risk relative to age. Blood sample white blood
cell proportions (CD8-T and CD4-T cells, natural killer cells, b-cells,
monocytes) were calculated from the methylation data [35, 36] and
included as covariates (technical confounders) in analyses with GrimAge
residuals as the outcome. As cell type composition may be confounded
with DNAm, even when DNAm-based variables are the exogenous
variable, we created a second GrimAge residual variable for use in
follow-up analyses of models in which GrimAge was the independent
variable in which variance associated with chronological age and cell type
estimates was regressed out from raw GrimAge estimates.
Neuropsychological measures (TRACTS cohort). We examined age-related
neurocognitive performance in two domains: inhibitory control and verbal
memory. Two measures of inhibitory control were analyzed: total commission
errors on the Affective Go/No-go task (AGNG) [37] and inhibition scores on the
color-word interference test (i.e., Stroop) from the Delis–Kaplan Executive
Function System [38]. Verbal memory recall was assessed using the California
Verbal Learning Test: Second Edition (CVLT-II) [39], in which participants’ recall
of a 16-item word list across ﬁve learning trials was summed. Additional
information is provided in the Supplementary Materials.
Metabolic and associated analytes acquired through clinical lab assays
(TRACTS cohort). We used standard measures of metabolic pathology (e.g.,
height, weight, cholesterol, and blood pressure) to calculate a latent metabolic
pathology variable and associated factor scores (Supplementary Materials and
Table S1). Higher scores index greater metabolic pathology and metabolic
syndrome (MetS) [40]. Total measured (as opposed to estimated from DNAm)
white blood cells (WBCs) and log-transformed C-reactive protein (CRP) values
were used to assess immune response and inﬂammation, respectively, and
log-transformed gamma-glutamyl transferase (GGT) was evaluated as an
index of systemic oxidative stress. These blood samples were processed and
shipped the same day of the blood draw to a clinical laboratory (Quest
Diagnostics, Cambridge, MA). Standardization procedures followed those set
by the College of American Pathologists.
Simoa-derived neurologic and inﬂammatory analytes (both cohorts). Neurology markers (neuroﬁlament light, GFAP, tau, BDNF, amyloid ß 40 and 42,
phosphorylated neuroﬁlament heavy chain, and NSE) and inﬂammation
analytes (IL-6, IL10, eotaxin, and TNF-α) were derived from plasma (from
the same blood draw as the other blood-based biomarkers) using Simoa®
bead technology in the TRACTS cohort (Quanterix, Billerica, MA). A subset
of these markers (IL-6, IL10, TNF-α, NSE, and BDNF) were also available in
the NCPTSD cohort. Additional information regarding cohort-speciﬁc
Simoa® methodology is available in the Supplementary Materials. Simoa®
markers were log-transformed and outliers >3 SD ± the mean removed.
MRI data acquisition and processing (TRACTS cohort). Structural imaging
data were available for 389 participants in the TRACTS cohort. Two
Magnetization Prepared Rapid Gradient Echo (MP-RAGE) T1-weighted
structural scans were acquired on a 3-Tesla Siemens Trio whole-body TIM
Trio MRI scanner (n = 361) or a Siemens Prisma scanner with Syngo D13D
software (n = 28). The two T1-weighted structural scans were averaged to
create a single high contrast-to-noise image. A scanner ﬂag was included
in analyses as a covariate to account for potential scanner differences.
Cortical thickness analysis was performed using the FreeSurfer image
analysis suite (version 5.3, http://surfer.nmr.mgh.harvard.edu; see Supplementary Materials).

Translational Psychiatry (2022)12:406

Data analysis
In both cohorts, associations between GrimAge residuals and residuals from
other estimates of DNAm age (Horvath, Hannum, and Levine/DNAmPheno
Age) were ﬁrst evaluated using correlational analyses. In the NCPTSD cohort,
psychiatric symptom scores were summed to create dimensional scores for
each diagnosis assessed via the SCID, and included in a conﬁrmatory factor
analysis to model the fear, distress, and externalizing latent variables. Because
PTSD shows associations with both internalizing and externalizing dimensions
of psychopathology and has previously been associated with advanced
epigenetic age [15], it was not included in the conﬁrmatory factor analysis, but
was instead included in regression models alongside the latent psychopathology factor scores. Indicators for each latent variable are notated in Table S2
and ﬁt statistics are provided in Table S1 (see also [35]). We then evaluated
these three psychopathology factor scores and PTSD severity as predictors of
GrimAge residuals in a hierarchical linear regression model, controlling for the
top three global ancestry PCs, sex, and estimated WBCs (from the DNAm data)
in the ﬁrst step of the regression. Next, we followed up on signiﬁcant factor
score effects by evaluating the individual diagnoses that comprised the factor.
We examined if effects observed in the NCPTSD cohort replicated in the
TRACTS cohort. As the TRACTS cohort did not assess all diagnoses included in
the NCPTSD cohort (e.g., ASPD), we were limited to evaluating associations
between GrimAge residuals and the available individual diagnoses. Covariates
replicated those included in the NCPTSD analyses.
Examination of health and biological correlates of GrimAge residuals
proceeded in each cohort based on the available data, such that
neuropsychological, metabolic, MRI, and Simoa® markers were examined in
TRACTS and a subset of Simoa® markers were examined in NCPTSD. We
evaluated if GrimAge residuals were associated with neurocognitive deﬁcits
that are commonly observed in aging—disinhibition and verbal memory
recall—in three regressions with age and sex included as covariates. A False
discovery rate (FDR) adjusted p value (padj, or q value) was used to account for
multiple testing across the three neuropsychological outcomes.
We next examined GrimAge residuals in association with the blood-based
biomarkers. Linear regression analyses controlling for age and sex were used
to test whether GrimAge residuals predicted the following separately
analyzed outcomes: MetS factor scores, CRP, GGT, total measured (not
estimated) WBC, four Simoa® markers associated with inﬂammation (IL-6, IL10,
eotaxin, and TNF-α), and eight Simoa® markers associated with neurodegeneration (neuroﬁlament light, GFAP, tau, BDNF, amyloid ß 40 and 42,
phosphorylated neuroﬁlament heavy chain, and NSE). A smaller subset of
Simoa® markers (IL-6, IL10, TNF-α, BDNF, and NSE) were available in the
NCPTSD cohort for replication analyses. FDR was used to correct for multiple
testing across 16 blood biomarker outcomes in TRACTS and ﬁve in NCPTSD.
We evaluated if previously identiﬁed associations between GrimAge
residuals and cortical thickness in regions associated with emotion- and
threat-regulation [19] replicated in our sample. To do so, measures of right
and left hemisphere orbitofrontal and posterior cingulate cortical thickness
were submitted to an omnibus hierarchical linear regression analysis in
which sex, age, and scanner were entered in an initial model and GrimAge
residuals were entered in the second step of the model. Multiple testing
adjusted p values for GrimAge residual main effect analyses were
determined using Monte Carlo null simulation with 10,000 replicates in
which GrimAge residuals were randomly permuted between subjects [41].
The analysis imposed multiple-testing control while taking into account
the correlations between the cortical thickness scores.
Finally, the main effect of the GrimAge residuals was also investigated in a
follow-up unbiased whole brain cortical thickness analysis (n = 361) in the
TRACTS cohort. The Freesurfer version 7.1 command line tools mris_preproc,
mri_surf2surf, and mri_glmﬁt and spatial smoothing of 10 mm full-width halfmaximum were used. Age, sex, and scanner were included in the model as
covariates. The command line tool mri_glmﬁt-sim was used to correct for
multiple comparisons with a vertex-wise/cluster forming threshold of
p < 0.0001 and a cluster-wise p value of p < 0.05. Signiﬁcant regions were
extracted for analyses featuring additional covariates.
Sensitivity analyses featuring additional covariates and GrimAge
residuals adjusted for both age and cell type composition were performed
on FDR signiﬁcant outcomes and are reported in the Supplementary
Materials.

RESULTS
Descriptive statistics
Participant characteristics and descriptive statistics for the NCPTSD
and TRACTS cohorts are listed in Table 1.
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Table 1.

Participant characteristics and descriptive statistics.
NCPTSD (N = 647)

Variable

M (SD)

TRACTS (N = 434)
n (%)

M (SD)

n (%)

Demographics
Sex (male)
Age

407 (62.9)
51.85 (10.60)

392 (90.3)
32.44 (8.63)

Race
White

525 (81.1)

322 (74.2)

80 (12.4)

37 (8.5)

8 (1.2)

6 (1.4)

American Indian/Alaska Native

57 (8.8)

3 (0.7)

Hawaiian/Other Paciﬁc Islander

2 (0.3)

2 (0.5)

38 (5.9)

2 (0.5)

Black/African American
Asian

Unknown
Psychiatric
Lifetime PTSD severity/Dx
# of Trauma types

60.12 (32.93)

389 (60.1)

9.90 (4.26)

69.00 (32.98)

351 (76.8)

1.95 (1.80)

Lifetime AUD severity/Dx

8.03 (7.81)

376 (58.8)

286 (65.9)

Lifetime Non-AUD SUD severity/
Dx

5.24 (9.53)

191 (29.7)

137 (31.6)

Lifetime ASPD severity/Dx

5.19 (5.80)

22 (4.8)

Neuropsychological
AGNG

11.56 (9.19)

Stroopb

26.59 (12.14)

CVLT-IIc

48.33 (9.88)

Biological
CRP (log)

−0.77 (0.29)

GGT (log)

1.39 (0.24)

WBC

6.28 (1.71)

AB40 (log)

2.32 (0.07)

AB42 (log)
BDNF (log)

0.91 (0.08)
3.41 (0.38)

3.10 (0.47)

GFAP (log)

1.79 (0.16)

NFL (log)

0.72 (0.19)

NSE (log)

4.32 (0.26)

4.07 (0.21)

TAU4 (log)

0.16 (0.23)

PNF (log)

1.41 (0.35)

Eotaxin (log)
IL10 (log)

1.61 (0.14)
−0.10 (26)

−0.16 (0.21)

IL-6 (log)

0.19 (0.31)

0.14 (0.27)

TNF-α (log)

0.53 (0.20)

0.43 (0.13)

NCPTSD National Center for PTSD cohort, TRACTS Translational Research Center for TBI and stress disorders cohort, M mean, SD standard deviation, PTSD
posttraumatic stress disorder, dx diagnosis, CRP C-reactive protein, GGT gamma-glutamyl transferase, WBC total measured white blood cell counts, AGNG
affective go/no-go task, CVLT-II California verbal learning test second edition, AB40/AB42 amyloid ß 40/42, BDNF brain-derived neurotrophic factor, GFAP glial
ﬁbrillary acidic protein, NFL neuroﬁlament light, NSE neuron-speciﬁc enolase, PNF phosphorylated neuroﬁlament heavy, IL10/6 interleukin 6/10, TNF-α tumor
necrosis factor.
a
Raw scores for total commission error = Total positive commissions + total negative commissions.
b
Scaled scores adjusted for performance = Inhibition – (Color naming + Word reading)/2.
c
Total words recalled across ﬁve learning trials.

GrimAge, chronological age, and other DNAm age estimates
in both cohorts
In the NCPTSD cohort, GrimAge estimates were highly correlated
with age (r = 0.88, p < 0.001) and with Horvath, Hannum, and
PhenoAge DNAm age (r range = 0.78–0.83, all ps < 0.001). Despite
high correlations among the raw DNAm measures, GrimAge residuals

showed weak associations with Horvath, Hannum, and PhenoAge
DNAm age residuals (r range = 0.14–0.24, p < 0.001), meaning that
they shared a maximum 5.67% of the variance with GrimAge
residuals. The overall pattern of results was similar in the TRACTS
cohort, except that GrimAge residuals were not signiﬁcantly
correlated with Horvath residuals (see Table S3).
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Table 2.

Psychopathology as a predictor of GrimAge residuals in both

cohorts.
NCPTSD
Variable

β

SE

B

p

Covariates:
PC1

0.075

9.148

4.616

PC2

−0.023

−2.722

4.443

0.540

PC3

−0.003

−0.397

4.594

0.931

0.064

7.720

4.646

0.097

CD8-T

0.048

CD4-T

−0.038

−3.163

3.245

0.330

NK

−0.241

−23.402

3.566

<0.001

B-cell

−0.145

−16.815

4.304

<0.001

Monocytes

−0.044

−7.601

6.932

0.273

0.344

3.178

0.359

<0.001

0.345

0.351

0.044

<0.001

Sex
Primary predictors
Externalizing
factor score

−0.120

−0.178

0.095

0.062

Fear factor score

0.018

0.008

0.025

0.738

Lifetime PTSD severity

0.056

0.008

0.006

0.215

Distress factor score

TRACTS
Covariates:
PC1

−0.186

−15.297

3.984

<0.001

PC2

0.022

2.064

4.485

<0.001

PC3

0.053

4.814

4.288

0.262

−0.233

−20.689

4.174

<0.001

CD8-T
CD4-T

−0.144

−9.883

3.346

0.003

NK

−0.238

−23.583

4.639

<0.001

B-cell

−0.051

−7.153

7.010

0.308

Monocytes

−0.108

−14.293

6.473

0.028

Sex

−0.150

−1.691

0.527

0.001

Primary predictors:
Lifetime AUD dx
Lifetime nonAUD SUD dx
Lifetime PTSD dx

0.077

0.541

0.339

0.112

0.104

0.747

0.339

0.028

0.149

1.165

1.220

0.001

Results based on hierarchical regression models with covariates entered
into the ﬁrst step and psychopathology variables entered in the second.
The △R2 coefﬁcients were signiﬁcant for the second step across models.
PC principal component, CD cluster of differentiation, NK natural killer, PTSD
posttraumatic stress disorder, AUD alcohol use disorder, SUD substance use
disorder, dx diagnosis, β standardized beta, B unstandardized beta,
SE standard error for unstandardized beta.
Bolded values reﬂect p < 0.05.

NCPTSD cohort: GrimAge residuals, PTSD, and
psychopathology
In the multiple regression model, externalizing factor scores were
signiﬁcantly associated with GrimAge residuals (b = 0.35, standardized [std] β = 0.35, p < 0.001). PTSD severity and the fear and
distress factor scores were not associated with GrimAge residuals
(Table 2). Follow-up analyses examining each component of the
externalizing spectrum revealed that non-alcohol use substance
use disorders (SUD; b = 0.11, std β = 0.20, p < 0.001) and ASPD
(b = 0.10, std β = 0.13, p = 0.017) predicted GrimAge residuals,
but lifetime alcohol use disorders (AUD) did not (b = 0.05, std
β = 0.08, p = 0.107). These effects remained signiﬁcant in sensitivity analyses (see Supplementary Materials).
Translational Psychiatry (2022)12:406

TRACTS cohort: GrimAge residuals, externalizing disorders,
and PTSD
Consistent with ﬁndings from the NCPTSD cohort, lifetime nonalcohol-use SUD signiﬁcantly predicted GrimAge residuals
(b = 0.75, std β = 0.10, p = 0.028), but lifetime AUD did not
(b = 0.541, std β = 0.08, p = 0.112) (Table 2). Lifetime PTSD
diagnosis was associated with GrimAge residuals (b = 1.17, std
β = 0.15, p = 0.001). These effects remained signiﬁcant in sensitivity analyses (see Supplementary Materials).
TRACTS cohort: GrimAge residuals and neuropsychological
constructs
GrimAge residuals were associated with greater errors on the
AGNG task (b = 0.38, std β = 0.14, padj = 0.021; Table 3). This effect
remained signiﬁcant in follow-up analyses (see Supplementary
Materials). GrimAge residuals were also associated with poorer
verbal memory recall on the CVLT (b = −0.372, std β = −0.12,
padj = 0.023; Table 3). This effect missed the threshold for
signiﬁcance (p = 0.065) in follow-up analyses (see Supplementary
Materials). GrimAge residuals and Stroop scores were not
signiﬁcantly associated (b = 0.35, std β = 0.05, padj = 0.318).
TRACTS cohort: GrimAge residuals and metabolic, immune,
and neurology analytes
As shown in Table 4, GrimAge residuals were signiﬁcantly
associated with the MetS factor scores (b = 0.002, β = 0.139,
padj < 0.001), CRP (b = 0.020, β = 0.220, padj < 0.001), GGT
(b = 0.012, β = 0.161, padj = 0.003), and total measured WBCs
(b = 0.167, β = 0.324, padj < 0.001). With regard to Simoa® markers,
GrimAge residuals were signiﬁcantly associated with GFAP
(b = −0.007, β = −0.133, padj = 0.021) and two inﬂammatory
markers: Eotaxin (b = 0.005, β = 0.111, padj = 0.050) and IL-6
(b = 0.023, β = 0.286, padj < 0.001). All effects remained signiﬁcant
in follow-up analyses (see Supplementary Materials).
NCPTSD Cohort: GrimAge residuals and immune and
neurology analytes
As shown in Table 4, the effect of GrimAge residuals on IL-6 that
was observed in the TRACTS cohort was replicated in the NCPTSD
cohort (b = 0.022, β = 0.317, padj < 0.001). GrimAge residuals were
also associated with TNF-α levels in the NCPTSD cohort (b = 0.007,
β = 0.156, padj < 0.001). All effects remained signiﬁcant in followup analyses (see Supplementary Materials).
TRACTS cohort: GrimAge residuals and neural integrity
The analysis evaluating associations between GrimAge residuals
and cortical thickness in two frontal regions of interest revealed
that GrimAge residuals were negatively associated with cortical
thickness in the right lateral orbitofrontal cortex (b = −0.006,
padj = 0.018; Table 5). This effect remained signiﬁcant in the
sensitivity analyses (see Supplementary Materials).
We also examined whole brain cortical thickness associations
with GrimAge residuals. There was a signiﬁcant negative
association between GrimAge residuals and whole brain
cortical thickness in the left fusiform gyrus that survived
multiple comparison correction (peak MNI coordinates =
−40.6 −73.0 −15.1, peak value = −4.876, number of vertices =
136, cluster size = 91.88 mm2, voxel-wise p < 0.0001, clustercorrected p < 0.03; Fig. 1). This remained signiﬁcant in the
sensitivity analyses (see Supplementary Materials).
DISCUSSION
Elucidating the association between psychopathology and risk for
early death is crucial for intervention and prevention efforts. Reliable
biomarkers of disease and mortality risk offer promising insight into
this association and have the potential to serve as useful clinical tools
for identifying underlying mechanisms and assessing risk and

S.E. Hawn et al.

6
Table 3.

GrimAge residuals as a predictor of neuropsychological constructs.
AGNG
β

Variable

Stroop
p

padj

CVLT-II

β

p

0.518

--

padj

β

p

padj

Covariats:
Sex
−0.003
Age
−0.041

0.011

0.835

--

0.955

--

0.033

0.006

0.901

--

0.429

--

−0.171

0.001

--

0.021
0.023

0.052

Primary Predictor:
GrimAge Residuals
−0.122

0.136
0.015

0.007

0.318

0.318

Results based on hierarchical regression models with covariates entered into the ﬁrst step and neuropsychological variables entered in the second. △R2
coefﬁcients were signiﬁcant for the second step across models with signiﬁcant second step effects.
AGNG affective go/no-go task, CVLT-II California verbal learning test: second edition, PTSD posttraumatic stress disorder, AUD alcohol use disorder, MDD major
depressive disorder; padj p value adjusted for multiple testing by controlling the false discovery rate (FDR) of 5%.
Bolded values reﬂect p or padj < 0.05.

Table 4.

Associations between GrimAge residuals and metabolic, immune, and neurology markers.
TRACTS

Variable

β

NCPTSD
p

padj

β

p

padj

Metabolic, immune, and oxidative stress
MetS

0.139

<0.001

<0.001

--

--

--

WBC

0.324

<0.001

<0.001

--

--

--

GGT

0.161

0.001

0.003

--

--

--

Inﬂammatory markers
CRP

0.220

<0.001

<0.001

--

--

--

Eotaxin

0.108

0.026

0.059

--

--

--

IL10

0.072

0.165

0.264

0.049

0.281

0.281

IL-6

0.286

<0.001

<0.001

0.341

<0.001

<0.001

TNF-alpha

0.077

0.135

0.240

0.156

<0.001

<0.001

Neurologic markers
GFAP
−0.132

0.021

--

--

--

0.387

--

--

--

0.008
NFL
−0.055
0.266
pNF

0.001

0.985

0.985

--

--

--

AB42

0.052

0.316

0.421

--

--

--

AB40

0.080

0.122

0.240

--

--

--

NSE

0.043

0.391

0.447

0.072

0.107

0.143

BDNF

0.043

0.386

0.447

0.071

0.114

0.143

Tau4

0.025

0.661

0.705

--

--

--

Results based on hierarchical regression models controlling for age and sex (covariate effects not shown for simplicity). The △R2 coefﬁcients were signiﬁcant
for the second step across models with signiﬁcant second step effects.
MetS metabolic syndrome, WBC total measured white blood cell count, GGT gamma-glutamyl transferase, CRP C-reactive protein, IL10/IL6 interleukin 10/6, TNFalpha tumor necrosis factor, GFAP glial ﬁbrillary acidic protein, NFL neuroﬁlament light, pNF phosphorylated neuroﬁlament heavy chain, AB42/AB40 amyloid
beta 40/42, NSE neuron-speciﬁc enolase, BDNF brain-derived neurotrophic factor, padj p value adjusted for multiple testing by controlling the false discovery
rate (FDR) of 5%.
Bolded values reﬂect padj < 0.05.

intervention efforts. We examined associations between the most
reliable biomarker of age-independent time-to-death to date,
GrimAge, broad dimensions of psychopathology, and PTSD, and
evaluated the neurobiological correlates of GrimAge. We found that

GrimAge residualized for chronological age was associated with
externalizing psychopathology, PTSD, and a wide range of agerelated neurocognitive and neurobiological biomarkers, which
suggests the clinical value of this DNAm index.
Translational Psychiatry (2022)12:406
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Table 5.

Associations between GrimAge residuals and cortical thickness in regions of interest.
RH OFC

Variable

b

LH OFC
p

padj

RH PCC
p

b

padj

b

LH PCC
p

padj

p

b

padj

Covariates:
0.051

0.065

--

0.033

0.220

--

−0.020

0.455

--

0.011

0.699

--

Sex

−0.022

0.401

--

−0.039

0.140

--

0.021

0.428

--

−0.018

0.513

--

Age

−0.007

0.000

--

−0.007

0.000

--

−0.006

0.000

--

−0.007

0.000

--

−0.006

0.007

0.016

−0.005

0.035

0.116

0.003

0.184

0.498

0.000

0.850

1.00

Scanner

Primary predictor:
GrimAge residuals

Results based on hierarchical regression models with covariates entered into the ﬁrst step and GrimAge residuals entered in the second. The △R2 was
signiﬁcant for the second step of the model predicting RH OFC.
RH right hemisphere, LH left hemisphere, OFC orbitofrontal cortex, PCC posterior cingulate cortex, padj p value adjusted for multiple testing.
Bolded values reﬂect p or padj < 0.05.

Fig. 1 Signiﬁcant whole brain cortical thickness results. In a whole brain cortical thickness analysis with a vertex-wise threshold of
p < 0.0001 and cluster corrected at p < 0.05, results revealed that there was a signiﬁcant negative association between GrimAge residuals and
the left fusiform gyrus. The color bar indicates the log 10 value for p values associated with the cluster-corrected results. LH = left hemisphere.

Psychopathology and shortened time-to-death
This is the ﬁrst study to investigate GrimAge in association with
broad dimensions of psychopathology. Results demonstrated
associations between externalizing psychopathology and
GrimAge residuals. These associations extended to two of the
individual components (i.e., non-alcohol SUD, ASPD) of the
broader externalizing dimension in the NCPTSD cohort and
the effect for non-alcohol SUD replicated in the independent
TRACTS cohort of young veterans. Notably, the magnitude of the
effect for the externalizing dimension (std β = 0.35) was roughly
double that for the individual disorders comprising this spectrum,
suggesting the biological relevance and statistical advantages of
modeling this common factor.
These results are consistent with prior research suggesting
that individual externalizing disorders are associated with
elevated risk for premature all-cause mortality [5]. We also
found a positive association between PTSD and GrimAge
residuals in the TRACTS cohort (though not the NCPTSD
cohort), replicating prior work for this disorder [19, 20].
Together, this highlights the critical need for assessment of
externalizing characteristics among trauma-exposed samples.
Whereas focus has historically been placed on the risk of death
related to behavior-based externalizing features (e.g., accidental, drug-related, death by suicide [42]), our ﬁndings suggest a
possible differential biological course to shortened time-todeath for externalizing psychopathology relative to internalizing. This, in conjunction with the greater effect size compared
to what was shown for individual disorders, is consistent with
research suggesting that broad dimensions of psychopathology that reﬂect common features of individual disorders
may offer an enhanced ability to identify biomarkers and
biological consequences of such psychopathology [8]. This was
further supported by our ﬁndings that GrimAge residuals
were associated with a wide variety of biomarkers spanning
inﬂammation, oxidative stress, metabolic dysregulation, and
neuropathology.
Translational Psychiatry (2022)12:406

GrimAge residuals and neurocognitive function
The link between shortened time-to death and externalizing
psychopathology in this study was consistent with our results
demonstrating an association between GrimAge residuals and
disinhibition, as disinhibition is at the core of externalizing
disorders [43]. Given the cross-sectional nature of the data, the
directionality between these variables remains unclear. It is
possible that disinhibition increases the risk for early mortality,
and/or that GrimAge is a biomarker for reduced cognitive
functioning in this domain. Consistent with prior work demonstrating associations between GrimAge residuals and overall
cognitive decline [18], we found that GrimAge residuals were
sensitive to worse verbal memory, suggesting GrimAge could be
useful in identifying individuals who would beneﬁt from early
cognitive interventions to preserve functioning.
GrimAge residuals and blood-based biomarkers
GrimAge residuals showed associations with a broad range of
blood-based biomarkers implicated in age-related disease and
premature mortality risk, including inﬂammation (CRP, WBC, IL-6,
and TNF-α), oxidative stress (GGT), neuropathology (GFAP), and
metabolic disease (MetS). One particularly novel ﬁnding is the
association between GrimAge residuals and GGT, a marker of
oxidative stress. Oxidative stress, a molecular mechanism fundamental to aging that is frequently implicated in disease processes,
leads to the depletion of antioxidants when chronically elevated,
eventually resulting in cell degeneration and apoptosis [44]. GGT is
a biomarker of cardiometabolic disease, MetS, and mortality risk
[45], and elevated GGT is an index of liver disease and alcohol
abuse [46]. Thus, GGT could be a mechanism underlying the
pathway between externalizing psychopathology and early death.
This is the ﬁrst study to demonstrate associations between
GrimAge residuals and ultra-sensitive Simoa® markers of inﬂammation and neurodegeneration. Prior research has failed to ﬁnd
associations between GrimAge residuals and proinﬂammatory
cytokines, but these were assayed using typical ELISA-based
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methods that are less sensitive to low levels of the analyte [20].
The effect of GrimAge residuals on IL-6 was replicated across our
two independent cohorts. These results highlight the value of
Simoa® in detecting what may be very early risk markers for
disease, even in a relatively young adult cohort. GrimAge was
sensitive to these inﬂammatory biomarkers and has the potential
to be used as a tool for identifying preclinical individuals and
preventing premature mortality.
To that end, GrimAge residuals were associated with GFAP, a
marker of astrocytic damage [47]. As GFAP is expressed primarily
in the brain, only trace or undetectable levels of GFAP are usually
observed in the blood. When GFAP is found in blood, it is typically
considered an index of astrocytic damage and disruption of
blood–brain barrier integrity [48]. This can occur in response to
brain damage, degeneration of the central nervous system (CNS),
or aging [47]. In this study, GrimAge residuals were negatively
associated with GFAP levels, which is the opposite direction of
effect as was hypothesized. That said, prior work has reported low
to very low levels of blood-based GFAP in patients with a variety
of neurological diseases, despite the presence of neurological
symptoms [48]. It is possible that rapid astroglial destruction (as in
the acute aftermath of severe TBI or an intracerebral hemorrhage)
may be required to observe increases in GFAP in blood [48]. We
would not expect to see evidence of this in our cohort, as veterans
with moderate-to-severe TBI were excluded from these analyses.
Although GFAP upregulation is linked to a range of acute and
chronic neuropathologies, there may be neuroprotective effects
associated with increased GFAP [49, 50], as its function is highly
context-and development speciﬁc; under certain circumstances,
increased GFAP can elicit neurogenesis [50]. Additional evaluation
of the association between GFAP and GrimAge is necessary to
better understand the potential role of GFAP in shortened time-todeath and the implications for altering the course of neurodegenerative diseases.
GrimAge residuals and cortical thickness
GrimAge residuals were associated with reduced thickness in the
right lateral orbitofrontal cortex, replicating prior results by Katrinli
et al. [19] and consistent with the evidence of frontal cortical thinning
with age [51]. The lateral orbitofrontal cortex is important for
inhibitory control [52], including regulation of emotion and threat
detection [53], and it could be that reduced cortical thickness in this
region partially contributes to the behavioral disinhibition commonly
observed in externalizing psychopathology.
A follow-up whole brain cortical thickness analysis further
suggested that GrimAge residuals were associated with reduced
cortical thickness in the left fusiform gyrus (FFG). The FFG is well
known for its role in facial, object, and word recognition [54].
Evidence also suggests it is implicated in dementia and aging.
Speciﬁcally, left FFG atrophy is evident among patients with semantic
dementia [55], with one study identifying the left FGG as the hub of
the neuroanatomical network predicting semantic processing among
patients with semantic dementia [56]. FFG volume has also been
shown to decrease over time as part of the healthy aging process
[57]. The association between GrimAge residuals and the integrity of
this region in this study further suggests the clinical relevance of the
GrimAge algorithm and indicates that monitoring semantic functioning, starting in young adulthood, among those with advanced
GrimAge may be warranted.
Limitations
Our ﬁndings should be considered in the context of several
limitations. First, our study was based on cross-sectional data,
precluding causal interpretation of the direction of effects.
Second, cohorts were primarily male, white, veteran participants,
limiting generalizability. That said, associations between GrimAge
residuals and externalizing disorders were demonstrated in two
independent cohorts of varying mean age, highlighting the utility

of GrimAge as a marker of increased risk for early death, even
among young individuals. Third, except for a subset of Simoa®
markers that were available in both cohorts, we were unable to
test for replication of many of the health correlates as most of
these data were only collected in the TRACTS cohort.
CONCLUSIONS
These results contribute to burgeoning literature suggesting a
meaningful role of GrimAge in the prediction of premature
mortality and morbidity. To date, GrimAge is unmatched in its
ability to predict age-related disease and time-to-death. Our
ﬁndings highlight the critical need for assessment of externalizing
characteristics among trauma-exposed samples. The consistency
of associations between GrimAge residuals and related constructs
(i.e., externalizing psychopathology, behavioral disinhibition,
frontal cortical thinning) and a range of other neurobiological
markers further support the clinical relevance of this DNAm-based
index. Given behavioral inhibition and externalizing pathology
tend to decrease with age [58, 59], these associations may hold
particular relevance for younger veterans. Notably, by using novel
biomarker technology that results in a 1000-fold increase in
immunoassay sensitivity, this study is the ﬁrst to detect some of
the earliest neurobiological correlates of elevated mortality risk
per DNAm patterns. This work has important clinical implications,
as lifestyle interventions have been shown to reverse other
DNAm-based metrics of biological aging [60] and might also
mitigate the risk of premature death. Replication among longitudinal and age-varying cohorts is needed to address questions of
generalizability and directionality. Doing so would also inform
whether interventions that reduce externalizing behaviors alter
neurobiology and mortality risk over a given period of time.
Additionally, longitudinal mediation analyses could shed light on
whether the various biomarkers signiﬁcantly associated with
GrimAge residuals in these data (e.g., GGT) serve as mechanisms
along the pathway between externalizing psychopathology and
early death. In conclusion, GrimAge may be a useful tool in
identifying those at greatest risk for early mortality, thereby
providing opportunities for disease treatment and, with early
identiﬁcation, disease prevention.
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